Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
Paychex Adds 4% On Better-than-expected Quarterly Results
-
Crypto Researcher Says Post Ethereum’s Merge, Bitcoin Could Be ‘Regulated Away’
-
Bitcoin Exchange Inflows Tap 6-Year Low as Investors Take Flight to Self-Custody
-
$BTC: IIF’s Chief Economist Calls Bitcoin “Just Another Bubble Asset”
-
Cryptos Slide Ahead Of Jackson Hole Symposium